AIPM statistics on pharmaceutical patent disputes: compulsory licensing, unfair competition, interim measures

AIPM statistics on pharmaceutical patent disputes: compulsory licensing, unfair competition, interim measures

20.11.26

The Association of International Pharmaceutical Manufacturers (AIPM) has released fresh statistics on intellectual property disputes in the pharmaceutical industry.

Between 2017 and 2 November 2026, Russian courts heard more than 180 such disputes (51+ INNs). There were about 30 of them in 2017–2021, versus more than 150 in 2022–2026. The focus has shifted from challenging patents to early generic launches and compulsory licenses.

Generics are launched 6–7 years before patent expiry (previously about 3 years on average), the share of localized products in disputes has grown from ≈20% to more than 55%, and the number of companies launching generics early or challenging patents has risen from 3 to 10. Disputes between Russian manufacturers are appearing for the first time (at least 7).

Compulsory licenses

Since 2022, courts have received at least 38 compulsory license cases; about 70% of the claims were filed under Article 1362(1) of the Civil Code (“insufficient use”). There are no criteria for such use, and many cases are heard behind closed doors.

On 18 December 2025, the Constitutional Court found the provision constitutional. In its view, the purpose of a license is to eliminate a shortage, and the license should be revoked once the market is saturated. It also proposed a preliminary assessment by the FAS or a government subcommission.

The Supreme Court upheld the extension of the license in the Sanofi/Vertex case (overturning the IP Rights Court (SIP) ruling) and reinstated a license for a veterinary drug (fluralaner).

FAS

Since 2024, the Federal Antimonopoly Service (FAS) has treated the early launch of a generic as unfair competition. The Supreme Court confirmed this in the axitinib case (Axelpharm), pointing to estoppel and to the fact that competition can also exist with a distributor.

In the bosutinib, osimertinib and ruxolitinib cases, the FAS decisions ultimately stood, while in the dapagliflozin case the SIP set them aside.

Interim measures

Courts almost always refuse interim measures, including after FAS decisions. For example, a court refused AstraZeneca’s request to freeze payments under a state contract, citing risks to drug supply. The ruling is under appeal (case No. А11-8306/2026).

In 2026, a generic manufacturer for the first time filed a claim asking the court to oblige rights holders not to obstruct the launch of its product.

Recommendations for market participants in light of the new realities

ParticipantRecommendations
OriginatorsMaintain stable supplies in the volumes the healthcare system needs to reduce the risk of a compulsory license. Build a position in court and at the FAS at the same time. Prepare evidence on market saturation and shortage criteria. Do not rely on interim measures; plan for long disputes. Review patent “families”: abuse of additional patents can turn against the owner (the dapagliflozin case).
Generic companiesAssess patent risks before launching a product and rely on opinions of patent attorneys. Avoid inconsistent positions (obtaining a license while denying infringement), since estoppel applies. For licenses, collect expert opinions on clinical demand and supply data. Account for the risk of unfair competition even without patent disputes.
Russian manufacturers with localization and SPICCheck the patent clearance of localized INNs, as the share of localized products in disputes is growing. Build possible litigation and antimonopoly risks into contracts and investment plans.
DistributorsCheck the patent status of the generics they supply: liability for unfair competition can arise for them too. Include warranties and compensation clauses in contracts with manufacturers in case of disputes.
Customers and suppliers in public procurementTrack FAS and court decisions on the INNs being procured (there is no single notification mechanism). Account for the risk of contracts being suspended or challenged.

What do market participants expect from regulators and courts?

  • Define the criteria for “insufficient use”,
  • introduce a mechanism for informing customers about FAS decisions,
  • consider administrative preclusion, as recommended by the Constitutional Court,
  • ensure a uniform approach to protecting preclinical and clinical trial data at the EAEU level.

Source

AIPM, “Updated AIPM statistics: intellectual property disputes”, 9 November 2026.